Keith Wheatley
Impact in
- Hematology top 0.01%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Genetics top 0.05%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 110
- Acute Myeloid Leukemia Research 103
- Multiple Myeloma Research and Treatments 20
- Chronic Myeloid Leukemia Treatments 20
- Hematopoietic Stem Cell Transplantation 16
-
- Retinoids in leukemia and cellular processes 32
- Co-authors
- Richard Gray (26 shared papers)Alan K. Burnett (60 shared papers)Richard Peto (5 shared papers)Richard Doll (5 shared papers)I. L. G. Sutherland (1 shared paper)Anthony H. Goldstone (30 shared papers)Robert K. Hills (51 shared papers)Ian Hann (23 shared papers)
- Journals
- Blood (59 papers)Journal of Clinical Oncology (33 papers)British Journal of Haematology (30 papers)Cochrane Database of Systematic Reviews (11 papers)Trials (9 papers)
- Partner nations
- United KingdomFranceUnited States
In The Last Decade
Keith Wheatley
251 papers receiving 26.3k citations
Keith Wheatley's Hit Papers
Peers
Comparison fields: 5 of 177
- Hematology 12.5k
- Genetics 4.1k
- Public Health, Environmental and Occupational Health 4.8k
- Neurology 2.3k
- Oncology 3.2k
Countries citing papers authored by Keith Wheatley
This map shows the geographic impact of Keith Wheatley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Wheatley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Wheatley more than expected).
Fields of papers citing papers by Keith Wheatley
This network shows the impact of papers produced by Keith Wheatley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Wheatley. The network helps show where Keith Wheatley may publish in the future.
Co-authors
The 25 scholars most cited alongside Keith Wheatley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 255 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mortality in relation to smoking: 40 years' observations on male British doctors Hit paper breakdown → | 1994 | 3910 |
| 2 | The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial Hit paper breakdown → | 1998 | 2096 |
| 3 | Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials Hit paper breakdown → | 2010 | 1298 |
| 4 | The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Hit paper breakdown → | 2001 | 1183 |
| 5 | Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors Hit paper breakdown → | 1994 | 925 |
| 6 | Association between premature mortality and hypopituitarism Hit paper breakdown → | 2001 | 822 |
| 7 | Randomised trial of prophylactic daily aspirin in British male doctors Hit paper breakdown → | 1988 | 790 |
| 8 | Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia Hit paper breakdown → | 2005 | 613 |
| 9 | Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial Hit paper breakdown → | 2010 | 524 |
| 10 | Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial Hit paper breakdown → | 2010 | 491 |
| 11 | 2005 | 475 | |
| 12 | 2007 | 446 | |
| 13 | 1998 | 419 | |
| 14 | 1999 | 338 | |
| 15 | 2001 | 337 | |
| 16 | Physiotherapy versus placebo or no intervention in Parkinson's disease Hit paper breakdown → | 2013 | 327 |
| 17 | 2012 | 325 | |
| 18 | 1999 | 311 | |
| 19 | 2008 | 294 | |
| 20 | 2012 | 293 |
About Keith Wheatley
Keith Wheatley is a scholar working on Hematology, Molecular Biology, Public Health, Environmental and Occupational Health, Genetics and Oncology, having authored 255 papers that have together received 27.2k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (103 papers), Acute Lymphoblastic Leukemia research (43 papers), Retinoids in leukemia and cellular processes (32 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (20 papers), Multiple Myeloma Research and Treatments (20 papers), Chronic Myeloid Leukemia Treatments (20 papers), Hematopoietic Stem Cell Transplantation (16 papers) and Sarcoma Diagnosis and Treatment (15 papers). The work is most often cited by research in Hematology (12.5k citations), Genetics (4.1k citations), Public Health, Environmental and Occupational Health (4.8k citations), Neurology (2.3k citations) and Oncology (3.2k citations). Keith Wheatley has collaborated with scholars based in United Kingdom, France and United States. Frequent co-authors include Richard Gray, Alan K. Burnett, Richard Peto, Richard Doll, I. L. G. Sutherland, Anthony H. Goldstone, Robert K. Hills, Ian Hann, David Grimwade and Helen M. Walker. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Cochrane Database of Systematic Reviews and Trials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.